Maury and colleagues were the first to describe the use of DM1 hESC-derived mesenchymal stem cells to evaluate 12,089 compounds for their capacity to modulate the number of nuclear aggregates of mutant DMPK mRNAs, thanks to a high-content screening [94]. Here, DMPK is linked to myotonic dystrophy type 1.